Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05635162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Study acronym: ZEBRA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 12 to 13v11
  2. Study sites: 11 to 12v10
  3. Study sites: 8 to 11v9
  4. Study sites: 5 to 8v8
  5. Study sites: 4 to 5v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 3 to 4v6
  2. Study sites: 2 to 3v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Apr 2024 to May 17, 2024
    v4
  4. Primary completion date: Nov 30, 2027 to Oct 2028
    • Start date: Nov 1, 2023 to Apr 2024
    • Study completion date: Dec 30, 2027 to Oct 2028
    • Eligibility criteria expanded, about 88 words
    v3
  5. Primary completion date: Mar 31, 2027 to Nov 30, 2027v2 Show 5 more changesShow less
    • Start date: Mar 1, 2023 to Nov 1, 2023
    • Study completion date: Apr 30, 2027 to Dec 30, 2027
    • Secondary endpoints: 6 to 7
    • Eligibility criteria expanded, about 2 words
    • Study description shortened, about 1 word
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)
Trial Details
NCT Number NCT05635162
Lead Sponsor University College, London
Collaborators: BeiGene
Conditions
(from sponsor)		 Mantle Cell Lymphoma
Related terms Lymphoma, Mantle-Cell
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov